latest update:
[TrialBase DB]

trial summary · NCT07650565

Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Systemic Sclerosis (SSc), sponsored by University Hospital, Montpellier. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07650565phase —enrollment 16start 2026-10-27

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The objective of the study is to establish an in vitro model using iPSCs to test the hypotheses developed. The primary objective is to generate, via the SAFE-IPS platform, 8 iPSC lines derived from blood samples taken from: * Two patients with severe/diffuse SSc with multi-organ involvement (with anti-SCl-70 autoantibodies) * Two of their healthy close relatives * Two patients with uncomplicated SSc with localized involvement (with non-SCl-70 autoantibodies) * Two of their healthy close relatives These 8 cell lines will be differentiated by several teams at the FHU REGENHAB into: * Immune cells (monocytes/macrophages, neutrophils, dendritic cells, B/T lymphocytes) * Mesenchymal stromal cells * Myocardial cells * Skin cells (fibroblasts) * Synovial cells * Bronchial cells * Endothelial cells This project aims to map cellular and tissue heterogeneity using iPSC lines obtained from patients with both severe and mild SSc, employing single-cell RNA-seq under various pathological conditions, with and without autologous (or even heterologous) autoimmune stimulation. For example, the percentages of different cell types comprising a tissue in these various situations will be calculated. Comparisons will be made with control groups using healthy iPSC lines by recruiting healthy subjects with the same genetic profile and gender as the patients.

Source record: https://clinicaltrials.gov/study/NCT07650565

Facts

registry idNCT07650565
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionSystemic Sclerosis (SSc)
sponsorUniversity Hospital, Montpellier
sponsor classOTHER
enrollment16
start date2026-10-27
primary completion2028-04
completion2028-04
results postednot reported

Conditions

  • Systemic Sclerosis (SSc)

Interventions

  • Blood Sample Collection

Countries

  • France

Intervention types: PROCEDURE

Work with this record